Details for New Drug Application (NDA): 213078
✉ Email this page to a colleague
The generic ingredient in BIVALIRUDIN is bivalirudin. There are fourteen drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the bivalirudin profile page.
Summary for 213078
Tradename: | BIVALIRUDIN |
Applicant: | Slate Run Pharma |
Ingredient: | bivalirudin |
Patents: | 0 |
Pharmacology for NDA: 213078
Mechanism of Action | Thrombin Inhibitors |
Suppliers and Packaging for NDA: 213078
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
BIVALIRUDIN | bivalirudin | INJECTABLE;INTRAVENOUS | 213078 | ANDA | Slate Run Pharmaceuticals, LLC | 70436-025 | 70436-025-80 | 1 INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION in 1 VIAL, SINGLE-DOSE (70436-025-80) |
BIVALIRUDIN | bivalirudin | INJECTABLE;INTRAVENOUS | 213078 | ANDA | Slate Run Pharmaceuticals, LLC | 70436-025 | 70436-025-82 | 10 INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION in 1 CARTON (70436-025-82) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INTRAVENOUS | Strength | 250MG/VIAL | ||||
Approval Date: | May 28, 2021 | TE: | AP | RLD: | No |
Complete Access Available with Subscription